Arvinas (ARVN) Share-based Compensation (2017 - 2026)
Arvinas (ARVN) posted quarterly Share-based Compensation of $12.1 million for Q1 2026, down 19.33% year-over-year from $15.0 million in Q1 2025, and up 42.35% quarter-over-quarter from $8.5 million in Q4 2025.
Analysis
Arvinas (ARVN) Share-based Compensation (2017 - 2026) Analysis & Trends
Arvinas' Share-based Compensation history runs 10 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- In Q1 2026, Share-based Compensation fell 19.33% year-over-year to $12.1 million; the TTM figure through Mar 2026 stood at $41.1 million (down 51.42% YoY), while the FY2025 annual figure was $44.0 million, down 50.11% from the prior year.
- Share-based Compensation for Q1 2026 stood at $12.1 million, up from $8.5 million in the prior quarter.
- The five-year high for Share-based Compensation was $24.7 million in Q3 2024, with the low at $8.5 million in Q4 2025.
- The 5-year median for Share-based Compensation is $18.3 million (2023), against an average of $17.1 million.
- The sharpest annual moves came in 2022 and 2025: Share-based Compensation surged 61.17% in 2022, then plunged 63.52% in 2025.
- Arvinas' Share-based Compensation stood at $20.1 million in 2022, then declined by 16.92% to $16.7 million in 2023, then surged by 39.52% to $23.3 million in 2024, then plunged by 63.52% to $8.5 million in 2025, then surged by 42.35% to $12.1 million in 2026.
- Business Quant data shows ARVN's Share-based Compensation at $12.1 million in Q1 2026, $8.5 million in Q4 2025, and $10.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Arvinas | 609.77 Mn | 41.87 Mn | - | 5.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 5.90 Mn |
| Mar 31, 2026 | 12.10 Mn |
| Dec 31, 2025 | 8.50 Mn |
| Sep 30, 2025 | 10.20 Mn |
| Jun 30, 2025 | 10.30 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 23.30 Mn |
| Sep 30, 2024 | 24.70 Mn |
| Jun 30, 2024 | 21.60 Mn |
| Mar 31, 2024 | 18.60 Mn |
| Dec 31, 2023 | 16.70 Mn |
| Sep 30, 2023 | 16.70 Mn |
| Jun 30, 2023 | 18.30 Mn |
| Mar 31, 2023 | 19.90 Mn |
| Dec 31, 2022 | 20.10 Mn |
| Sep 30, 2022 | 18.80 Mn |
| Jun 30, 2022 | 20.00 Mn |
| Mar 31, 2022 | 16.60 Mn |
| Dec 31, 2021 | 17.00 Mn |
| Sep 30, 2021 | 15.22 Mn |